Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) is Tao Capital Management LP’s 10th Largest Position

Tao Capital Management LP decreased its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 97.5% during the 3rd quarter, Holdings Channel.com reports. The firm owned 5,683 shares of the company’s stock after selling 221,671 shares during the period. Ginkgo Bioworks accounts for approximately 0.0% of Tao Capital Management LP’s portfolio, making the stock its 10th biggest position. Tao Capital Management LP’s holdings in Ginkgo Bioworks were worth $46,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the stock. Paloma Partners Management Co purchased a new stake in shares of Ginkgo Bioworks during the first quarter worth approximately $28,000. Algert Global LLC acquired a new position in Ginkgo Bioworks during the 2nd quarter worth approximately $36,000. Russell Investments Group Ltd. increased its position in shares of Ginkgo Bioworks by 9,440.6% in the 1st quarter. Russell Investments Group Ltd. now owns 31,961 shares of the company’s stock valued at $37,000 after purchasing an additional 31,626 shares during the last quarter. Wellington Wealth Strategies LLC. acquired a new stake in shares of Ginkgo Bioworks in the 2nd quarter valued at $41,000. Finally, Thoroughbred Financial Services LLC purchased a new stake in shares of Ginkgo Bioworks during the 2nd quarter worth $70,000. Institutional investors and hedge funds own 78.63% of the company’s stock.

Analyst Ratings Changes

DNA has been the topic of several recent analyst reports. BTIG Research raised their price target on Ginkgo Bioworks from $0.20 to $7.00 and gave the company a “sell” rating in a research note on Friday, August 23rd. TD Cowen increased their price objective on Ginkgo Bioworks from $3.00 to $10.00 and gave the company a “buy” rating in a report on Friday, September 20th. Three analysts have rated the stock with a sell rating, one has given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $4.58.

Ginkgo Bioworks Trading Up 1.9 %

Shares of DNA opened at $6.45 on Wednesday. Ginkgo Bioworks Holdings, Inc. has a 1-year low of $5.26 and a 1-year high of $75.20. The stock has a market capitalization of $358.46 million, a PE ratio of -0.49 and a beta of 1.09. The company has a fifty day moving average of $7.81.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.